.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Federal Trade Commission
Merck
McKesson
Cipla
Chubb
Citi
UBS
Daiichi Sankyo

Generated: December 14, 2017

DrugPatentWatch Database Preview

GLUCOPHAGE XR Drug Profile

« Back to Dashboard

When do Glucophage Xr patents expire, and when can generic versions of Glucophage Xr launch?

Glucophage Xr is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in twelve countries and thirty supplementary protection certificates in eleven countries.

The generic ingredient in GLUCOPHAGE XR is metformin hydrochloride. There are forty-eight drug master file entries for this compound. One hundred suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
Drug patent expirations by year for GLUCOPHAGE XR

Pharmacology for GLUCOPHAGE XR

Ingredient-typeBiguanides
Drug ClassBiguanide

Medical Subject Heading (MeSH) Categories for GLUCOPHAGE XR

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bristol Myers SquibbGLUCOPHAGE XRmetformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021202-001Oct 13, 2000AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbGLUCOPHAGE XRmetformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021202-004Apr 11, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbGLUCOPHAGE XRmetformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021202-001Oct 13, 2000AB1RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Bristol Myers SquibbGLUCOPHAGE XRmetformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL021202-004Apr 11, 2003ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GLUCOPHAGE XR

Country Document Number Estimated Expiration
Eurasian Patent Organization200000968► Subscribe
Brazil9908911► Subscribe
Eurasian Patent Organization003101► Subscribe
New Zealand506202► Subscribe
Japan4523153► Subscribe
Australia736951► Subscribe
African Regional IP Organization (ARIPO)1224► Subscribe
Canada2320900► Subscribe
European Patent Office2332522► Subscribe
Japan2002506812► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GLUCOPHAGE XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00677Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121
2014000071Germany► SubscribePRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
9 5017-2014Slovakia► SubscribePRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
2014026Lithuania► SubscribePRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
C0028France► SubscribePRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124
2008013,C1412357Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
5006-2008Slovakia► SubscribePRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
00524Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
00569Netherlands► SubscribePRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720
/2012Austria► SubscribePRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Cerilliant
Johnson and Johnson
Mallinckrodt
Argus Health
Cantor Fitzgerald
Dow
Citi
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot